Nextcure provides business update and reports second quarter 2023 financial results

Beltsville, md., aug. 03, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results.

NXTC Ratings Summary

NXTC Quant Ranking